Biogen’s Alzheimer’s drug is unlikely to win E.U. approval. November 17, 2021 Auto Bot Aduhelm (Drug), alzheimer's disease, Biogen Inc, Europe, European Medicines Agency, Medicare 0 The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.